NCCN VERSION 2 2015

177 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-102
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
and first-line chemotherapy as treatment for patients with metastatic
breast cancer (MBC) [abstract]. J Clin Oncol 2010;28(Suppl
15):Abstract 1005. Available at:
.
477. BRIEFING BOOK, ONCOLOGY DRUGS ADVISORY
COMMITTEE MEETING, AVASTIN (Bevacizumab). Genentech, Inc., A
Member of the Roche Group; 2010. Available at:
Materials/Drugs/OncologicDrugsAdvisoryCommittee/UCM219228.pdf.
478. Seidman A, Berry DA, Cirrincione C, et al. Randomized phase III
trial of weekly compared with every-3-weeks paclitaxel for metastatic
breast cancer, with trastuzumab for all HER-2 overexpressors and
random assignment to trastuzumab or not in HER-2 nonoverexpressors:
final results of Cancer and Leukemia Group B protocol 9840. J Clin
Oncol 2008;26:1642-1649. Available at:
.
479. Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in
breast cancer: NCCN Task Force report and recommendations. J Natl
Compr Canc Netw 2006;4 Suppl 3:1-22. Available at:
480. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between
local and central laboratory HER2 testing in the breast intergroup trial
N9831. J Natl Cancer Inst 2002;94:855-857. Available at:
.
481. Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of
Clinical Oncology/College of American Pathologists guideline
recommendations for human epidermal growth factor receptor 2 testing
in breast cancer. J Clin Oncol 2007;25:118-145. Available at:
.
482. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab
plus docetaxel for metastatic breast cancer. N Engl J Med
2012;366:109-119. Available at:
.
483. Ewer M, Baselga J, Clark E, et al. Cardiac tolerability of
pertuzumab plus trastuzumab plus docetaxel in patients with HER2-
positive metastatic breast cancer in the CLEOPATRA study [abstract]. J
Clin Oncol 2012;30 (Suppl_15):Abstract 533. Available at:
_view&confID=114&abstractID=95049.
484. Cortés J, Baselga J, Im Y, et al. Quality of life assessment in
CLEOPATRA, a phase III study combining pertuzumab with
trastuzumab and docetaxel in metastatic breast cancer [abstract]. J Clin
Oncol 2012 30 (Suppl_15) Abstract 598 Available at:
_view&confID=114&abstractID=95084.
485. Datko F, D'Andrea G, Dickler M, et al. Phase II study of
pertuzumab, trastuzumab, and weekly paclitaxel in patients with
metastatic HER2-overexpressing metastatic breast cancer [abstract].
Cancer Research 2012;72:Abstract P5-18-20. Available at:
eetingAbstracts/P5-18-20.
486. Paclitaxel, trastuzumab, and pertuzumab in the treatment of
metastatic HER2-positive breast cancer (Clinical Trial ID:
NCT01276041). Available at:
. .
487. Perez E, Lopez-Vega J, Mastro L, et al. A combination of
pertuzumab, trastuzumab, and vinorelbine for first-line treatment of
patients with HER2-positive metastatic breast cancer: An open-label,
two-cohort, phase II study (VELVET) [abstract]. J Clin Oncol 2012;30
(Suppl_15):Asbtract TPS653. Available at:
_view&confID=114&abstractID=93917.